The nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma) has been shown to play a crucial role in adipogenesis. In recent years, there has been an interest in the role of PPARgamma in cancer. Colon cancer represents one of the leading causes of death in the United States. PPARgamma is expressed at high levels in normal and malignant colonic tissue. Therefore, we have been interested in understanding the role of this receptor in the colon.. Interestingly, the role of PPARgamma in the colon has been controversial with studies indicating both anti- and pro-cancer effects. Recently we have demonstrated in mice heterozygous at the PPAR? locus, that PPARgamma is playing a tumor suppressor role in the colon. Since PPARgamma is a tumor suppressor, the presence of PPARgamma in colonic tumors and cells suggests a disconnect between PPARgamma function and expression. Several studies have shown that PPARgamma is inactivated following MAPKinase-mediated phosphorylation of a conserved serine residue. Several pathways that lead to activation of the MAPKinase pathway have been shown have increased activity in colon cancer. This suggests that one possible reason for the presence of PPARgamma in colon cancer, and discrepancy in response to PPARgamma ligands could be due to PPARgamma phosphorylation. This proposal describes several experiments to critically evaluate the role of PPARgamma phosphorylation in colon cancer. Using pharmacological and eventually genetic approaches we will examine the role phosphorylation of PPARgamma on colon cancer cell growth and gene expression both in vitro and in vivo. A crucial aspect of these studies will be to determine possible mechanisms for the loss of PPARgamma activity due to phosphorylation. This will entail examining the ability of cofactors, both known and potentially novel, to interact in a phospho-dependent manner. Understanding the mechanism of phosphorylation-mediated inactivation of PPARgamma will not only provide insight in to the role of PPARgamma phosphorylation in colon cancer, but also other diseases where PPARgamma has been shown to play a role such as atherosclerosis and diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01DK064685-03
Application #
6899267
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Podskalny, Judith M,
Project Start
2003-09-15
Project End
2008-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
3
Fiscal Year
2005
Total Cost
$113,938
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Montal, Emily D; Dewi, Ruby; Bhalla, Kavita et al. (2015) PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. Mol Cell 60:571-83
Bhalla, Kavita; Liu, Wan-Ju; Thompson, Keyata et al. (2014) Cyclin D1 represses gluconeogenesis via inhibition of the transcriptional coactivator PGC1?. Diabetes 63:3266-78
Girnun, Geoffrey D (2012) The diverse role of the PPAR? coactivator 1 family of transcriptional coactivators in cancer. Semin Cell Dev Biol 23:381-8
Bhalla, Kavita; Hwang, Bor Jang; Dewi, Ruby E et al. (2012) Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 5:544-52
Bhalla, Kavita; Hwang, Bor Jang; Choi, Jang Hyun et al. (2011) N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor ? ligand with partial and full agonist activity in vitro and in vivo. J Biol Chem 286:41626-35
Bhalla, Kavita; Hwang, Bor Jang; Dewi, Ruby E et al. (2011) PGC1? promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res 71:6888-98
Girnun, Geoffrey D; Chen, Liang; Silvaggi, Jessica et al. (2008) Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 14:6478-86
Girnun, Geoffrey D; Naseri, Elnaz; Vafai, Scott B et al. (2007) Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11:395-406
Drori, Stavit; Girnun, Geoffrey D; Tou, Liqiang et al. (2005) Hic-5 regulates an epithelial program mediated by PPARgamma. Genes Dev 19:362-75